• Henry Ford Health Offers Multi-Cancer Early Detection Blood Test, New At-Home Celiac Risk Gene Test, More

    Sep 29 | Diagnostics World News | An RNA-based diagnostic workflow for detecting mRNA expression of standard breast cancer biomarkers; an automated TB test for immunocompromised patients; a companion diagnostic for detecting genomic alterations; and more. More
  • Follow the Money: CDC Funds HIV Self-Testing Program, World’s First Acute Rheumatic Fever Diagnostic Test, More

    Sep 28 | Diagnostics World News | Funding for voice-based diagnostics, machine learning algorithms that detect and stratify pulmonary hypertension, immunohistochemistry cancer diagnostics, and more. More
  • Leading-Edge Approaches To Early Cancer Detection

    Sep 22 | Diagnostics World News | Emerging approaches to the early detection of cancer were highlighted during the recent Next Generation Dx Summit held in Washington, D.C. Representatives from diagnostics companies Oxomics, Elypta, Micronoma, and Rivela Diagnostics took turns making their case for a new generation of technologies hunting for elusive molecular signatures of a highly heterogenous group of diseases. More
  • Promise Of Liquid Biopsies Coming To Light

    Sep 21 | Diagnostics World News | Ongoing collaboration between the fields of immunotherapy and liquid biopsy has opened vast opportunities to improve the care of cancer patients, including the prevention of full-blown disease or relapse. It was also the focus of several talks at the recent Next Generation Dx Summit, including a keynote on the long-hoped-for promise of liquid biopsy approaches for diagnosing and treating solid tumors. More
  • The NIH Launches a $300M Funding Initiative for Next-Generation COVID-19 Diagnostics

    Sep 20 | Diagnostics World News | The National Institutes of Health (NIH) seeks to award up to $300 million to diagnostic test manufacturers for developing improved next-generation COVID-19 tests. The two main objectives will be to increase testing performance and accessibility. More
  • Long COVID and Chronic Fatigue Syndrome Have A Lot In Common

    Sep 19 | Diagnostics World News | Evidence is emerging that long COVID (formally “post-acute sequelae SARS-CoV-2 infection,” or PASC) bears a striking, molecular-level resemblance to the disabling and complex illness now known as myalgic encephalomyelitis/chronic fatigue syndrome. More
  • Molecular Diagnostics: A Trusted Option for Hospitalized Patient Care

    Sep 19 | Diagnostics World News | Numerous studies have confirmed the reliability of rapid, comprehensive molecular diagnostic panels for identifying antimicrobial resistance markers. With advances in molecular diagnostic testing methods, relying on culture results alone is no longer an adequate approach. More
  • MIT Ultrasound Sticker Continuously Monitors Deep Organs for 48 Hours

    Sep 19 | Diagnostics World News | An MIT engineering team invented a new ultrasound sticker, enabling continuous high-resolution imaging for up to 48 hours. More
  • Mount Sinai Aims To Enroll One Million People In Genetic Sequencing Project

    Sep 15 | Diagnostics World News | The greater New York metropolitan area is the epicenter of an ambitious human genome sequencing research project newly launched by Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai. If the vision is realized, Mount Sinai will enroll a million patients into a study over the next five years that will sequence and analyze the DNA in their blood to tease out the role of genetics and environment on health. More
  • IVDR Creating ‘Significant Challenges’ For Global Precision Medicine Trials

    Sep 13 | Diagnostics World News | The impact of Europe’s In Vitro Diagnostic Medical Devices Regulation on global trials for precision medicine was shared at the recent Next Generation Dx Summit held in Washington, DC. IVDR is finally coming into force and creating “significant challenges” for pharmaceutical companies sponsoring studies involving biomarker testing on EU patient samples. More
View more articles

 
DXX-Industry-spotlight

bioready-citrate-gold-nanoshells


BioReady Citrate Gold Nanoshells

If you are looking for a probe that offers increased sensitivity, lower antibody usage, and the convenience of passive conjugation, you’ve come to the right place. Introducing BioReady Citrate Gold Nanoshells, enabling enhanced sensitivity for your lateral flow assay.

Learn more